Navigation Links
EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements

The European Food Safety Authority (EFSA) concludes no safety concerns for the use of chromium picolinate in food supplements, in response to Nutrition 21's Application to market Chromax(R) chromium picolinate in Europe.

PURCHASE, N.Y., June 30 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (Nasdaq: NXXI), the developer and marketer of nutritional supplements under the Iceland Health(R) and Diabetes Essentials brands, announced today that the European Food Safety Authority (EFSA) released its safety assessment supporting the use of chromium picolinate in food supplements in the European Union (EU). In its safety assessment, the EFSA concluded that chromium picolinate does not present a safety concern when used as a source of chromium in food supplements. This assessment is an initial step in the procedure for the formal EU approval of chromium picolinate as an acceptable form of supplemental chromium.

To assist Nutrition 21 in the submission of data for the EFSA to conduct its safety assessment the Company retained Cantox Health Sciences International, a leading international scientific and regulatory consulting firm. Nigel Baldwin, Ingredient Safety Expert from Cantox Health Sciences International, stated, "The EFSA's review and published opinion show the level of detail that we and Nutrition 21 went through to clearly demonstrate chromium picolinate as the form of chromium with the most safety data behind it. We are pleased with the EFSA's safety assessment of chromium picolinate. The standards set by the EFSA are the gold standards for the rest of the world and we believe this bodes well for Nutrition 21."

Chromax chromium picolinate is Nutrition 21's top selling nutritional supplement ingredient in the U.S. Approval of this ingredient in the EU would allow Nutrition 21 to enter into these new markets. William J. Levi, Vice President - Ingredients for Nutrition 21, stated, "This is an exciting development for our Ingredients business. Expansion into the European Union is an important component of our growth strategy. We already have active business development projects with potential strategic customers, and expect to announce an exclusive arrangement with a leading European ingredients manufacturer to distribute Chromax chromium picolinate throughout Europe upon formal EU approval."

James Komorowski, Vice President, Research & Development of Nutrition 21, commented, "The safety of Chromax chromium picolinate continues to be supported by numerous independent expert reviews worldwide. This is extremely important, particularly in recent times when the safety of certain dietary supplements is being questioned. The EFSA's conclusion on chromium picolinate provides our future EU customers with the added security of knowing this product is safe as they make educated decisions on what supplements to purchase."

European Food Safety Authority (EFSA)

The European Food Safety Authority (EFSA) is the keystone of European Union (EU) risk assessment regarding food and feed safety. In close collaboration with national authorities and in open consultation with its stakeholders, EFSA provides independent scientific advice and clear communication on existing and emerging risks.

About Nutrition 21

Nutrition 21, Inc. (NASDAQ: NXXI), headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health and wellness products include: Iceland Health Chromax(R), Iceland Health Advanced Memory Formula(TM), Diabetes Essentials, Iceland Health(R) Maximum Strength Omega-3 and Iceland Health(R) Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center stores throughout the United States and internationally. For more information please visit

Safe Harbor Provision

This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K/A for the year ended June 30, 2008. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.

    Company Contact:                     Investor Contact:
    James Komorowski, M.S., C.N.S.       Alan Kirschbaum
    Vice President                       Chief Financial Officer
    914-701-4500                         914-701-4500

SOURCE Nutrition 21, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Syngenta Issues EUR 500 Million Eurobond
2. Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.
4. Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA
5. Amylin Issues Statement in Response to Carl Icahn
6. Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
8. Beacon Equity Issues Trade Alerts on Market Movers: CAH, LEAP, FISV, PBG, ARNA, LEN
9. Assembling cells into artificial 3-D microtissues, including a tiny gland
10. NPSF Issues New Universal Patient Compact During Patient Safety Awareness Week
11. Beacon Equity Issues Technical Trade Alerts on Drug Manufacturer Stocks: FRX, TEVA, AGN, CEPH, VRTX, ADLR
Post Your Comments:
(Date:10/8/2015)... IRVINE, Calif. , Oct. 8, 2015 ... announced its expansion into the North American market with ... Asia and Europe ... a pioneer of Target Enrichment methodology and sample preparation ... or NGS, facilitates both hereditary and somatic genetic testing ...
(Date:10/8/2015)... 2015  The ALS Association, in partnership with Prize4Life, ... to revolutionize communication technology solutions for people living with ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease ... the spinal cord. Eventually, people with ALS lose the ... leads to total paralysis and death within two to ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: ... develop and commercialize intellectual property rights belonging to The University of British Columbia ... affords exclusive worldwide rights to intellectual property based on use of the ProMIS™ ...
(Date:10/7/2015)... ... October 07, 2015 , ... The Riordan-McKenna Institute ( ... educational seminar on the latest advances in adult stem cell therapy for orthopedic ... pm at the Hilton Dallas/Southlake Town Square in Southlake, Texas. , RMI offers ...
Breaking Biology Technology:
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... ) focused on bringing the life saving ... said today that Matthew Schissler, founder and CEO, in ... Company is very close to becoming cash flow positive.The ...
... CRY ), a biomaterials, medical device and tissue processing company, ... results will be released on Thursday, February 19, 2009. ... at 10:00 a.m. Eastern Time, February 19, 2009, to discuss ... by Steven G. Anderson, president and CEO of CryoLife, Inc.To ...
... INCHEON, South Korea, Feb. 5 The Centers for ... Korean,biopharmaceutical company, have signed a Letter of Intent to ... protect people exposed to,the rabies virus. , ... rabies is a two-step procedure.,First, rabies immune globulin (RIG) ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring device ... 2015. So says a new report on the industry from ... segment dominate the market, followed by continuous glucose monitoring and ... on the market for these products in its latest report, ... , ...
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
(Date:9/28/2015)... 2015  The monitoring of vital signs, such ... is an essential component of patient assessment. Changes ... in a patient,s condition. However, in general care ... taken during routine observation rounds only once every ... between these observation rounds, the warning signs can ...
Breaking Biology News(10 mins):
... it can damage blood vessels and increase the risk of ... he can thin the human blood by subjecting it to ... physics at Temple University, has pioneered the use of electric ... engines and pipelines. Now, he is using the same magnetic ...
... coastal areas in Africa can rarely utilise their entire fishing ... near the coast. Research carried out by economist Kofi Vondolia ... of fish stocks is significant to fish management. ... allows foreign fishing fleets to utilise the zones further out ...
... the Virginia Institute of Marine Science (VIMS) shows that jellyfish ... altering marine food webs by shunting food energy from fish ... frequency of jellyfish blooms in coastal and estuarine waters around ... impact on marine food webs is likely to increase into ...
Cached Biology News:
... preparation of the catalytic subunit of bovine ... isolated from the yeast Pichia pastoris to ... It recognizes the sequence Asp-Asp-Asp-Asp-Lys and cleaves ... The enzyme can be used to cleave ...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
Biology Products: